Sera Prognostics
Open
$2.10
Prev. Close
$2.00
High
$2.10
Low
$2.10
Market Snapshot
$76.8M
-2.4
-0.99
$77K
72
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
emptyResult
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Recently from Cashu
Sera Prognostics Advances Neonatal Health with New Prematurity Risk Insights and Funding Success
Sera Prognostics Unveils New Insights on Prematurity Risk in Neonatal Health Sera Prognostics Inc., recognized as The Pregnancy Company®, continues to spearhead advancements in maternal and neonatal h…
Sera Prognostics Explores Innovations at SIGEP World 2025 for Maternal Health Solutions
Sera Prognostics Seizes Opportunities at SIGEP World 2025 The upcoming SIGEP World 2025, set to take place in Rimini, Italy, from January 18 to 22, serves as a pivotal platform for companies like Sera…
Sera Prognostics Innovates Maternal Health with New Testing and Awareness Initiatives
Sera Prognostics Drives Innovation in Maternal Health with New Initiatives Sera Prognostics Inc., recognized as The Pregnancy Company®, is making significant strides in enhancing maternal and neonatal…